Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state

The American Journal of Cardiology
D J Kereiakes

Abstract

Several patient subgroups appear to benefit preferentially from inhibition of platelet glycoprotein (GP) IIb/IIa receptors. In clinical trials the GP IIb/IIa blocker abciximab (ReoPro; Lilly) proved both safe and effective in improving outcomes after coronary interventions. Endpoints of death, myocardial infarction (MI), and need for urgent intervention were significantly decreased in a randomized placebo-controlled trial of patients treated with abciximab in conjunction with either low-dose or standard-dose weight-adjusted heparin during elective percutaneous coronary revascularization. In addition, studies have shown that patients undergoing unplanned stent deployment or ablative technologies benefit from GP IIb/IIa blockade. Patients undergoing saphenous vein graft intervention also derive specific benefits. These agent--specifically abciximab, eptifibatide (INTEGRILIN; Cor/Schering), and tirofiban--have also benefited patients with the acute coronary syndromes (e.g., unstable angina) by decreasing ischemic events.

References

Jun 12, 1997·The New England Journal of Medicine·UNKNOWN EPILOG Investigators
Jul 15, 1997·The American Journal of Cardiology·S K SharmaJ A Ambrose
Feb 19, 1998·Circulation·D S BaimR E Kuntz

❮ Previous
Next ❯

Citations

Jul 20, 2010·Journal of Interventional Cardiology·Cedric DelhayeRon Waksman
Apr 27, 2000·The American Journal of Cardiology·D L BhattE J Topol
Nov 21, 2001·Current Controlled Trials in Cardiovascular Medicine·Dean J Kereiakes
Dec 28, 2007·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Viroj Wiwanitkit
Jan 31, 2006·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Viroj Wiwanitkit
Jul 22, 2004·American Journal of Therapeutics·Ramesh M GowdaTerrence J Sacchi
Mar 14, 2001·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·E J DippelC W Abbottsmith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.